Literature DB >> 973989

Effects of aspirin and prostaglandin E2 on secondary phase aggregation responses of schizophrenic patients treated with chlorpromazine.

D J Boullin, M W Orr.   

Abstract

We investigated the effects of oral aspirin 900 mg upon the platelet aggregation responses to 5-hydroxytryptamine, dopamine or N-dimethyl dopamine in schizophrenic patients chronically treated with chlorpromazine. Most subjects showed enchanced aggregation responses (that is appearance of secondary phase aggregation) to these agents prior to aspirin administration. When aggregation was re-tested 23.5 h after aspirin the secondary phase of the enhanced aggregation responses was abolished. Addition of 0.14-0.3 mumol/l prostaglandin E2 15 s after inducing aggregation partially restored the secondary phase. The observed secondary phase of aggregation may be due to increased prostaglandin synthesis or release.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 973989      PMCID: PMC1428953          DOI: 10.1111/j.1365-2125.1976.tb00649.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  4 in total

1.  Platelet physiology and abnormalities of platelet function (first of two parts).

Authors:  H J Weiss
Journal:  N Engl J Med       Date:  1975-09-11       Impact factor: 91.245

2.  Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine.

Authors:  D J Boullin; H F Woods; R P Grimes; D G Grahame-Smith
Journal:  Br J Clin Pharmacol       Date:  1975-02       Impact factor: 4.335

3.  Effect of prostaglandin E 2 and aspirin on the secondary aggregation of human platelets.

Authors:  H Shio; P Ramwell
Journal:  Nat New Biol       Date:  1972-03-15

4.  A comparison of an effect of different anti-inflammatory drugs on human platelets.

Authors:  J R O'Brien; W Finch; E Clark
Journal:  J Clin Pathol       Date:  1970-09       Impact factor: 3.411

  4 in total
  1 in total

Review 1.  Assessment of anti-psychotic drugs.

Authors:  A V Mackay
Journal:  Br J Clin Pharmacol       Date:  1981-03       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.